Evidence map›Paper›PMID 26597254›Full record

Trial reportThe Journal of infectious diseases2016

Artesunate/Amodiaquine Versus Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria in Uganda: A Randomized Trial.

Adoke Yeka, Ruth Kigozi, Melissa D Conrad, Myers Lugemwa, Peter Okui, Charles Katureebe, Kassahun Belay, Bryan K Kapella, Michelle A Chang, Moses R Kamya and 3 more

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 2 pooled it
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Changing Antimalarial Drug Sensitivities in Uganda.Antimicrobial agents and chemotherapy · 2017
    Trial
  11. Trial
  12. Trial
  13. Article
  14. bioRxiv : the preprint server for biology · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 3 countries.

Adoke YekaSchool of Public Health, Makerere University College of Health Sciences Infectious Diseases Research Collaboration, President's Malaria Initiative, Kampala, Uganda.
Ruth KigoziInfectious Diseases Research Collaboration, President's Malaria Initiative, Kampala, Uganda.
Melissa D ConradDepartment of Medicine, University of California, San Francisco.
Myers LugemwaNational Malaria Control Program, Ministry of Health, President's Malaria Initiative, Kampala, Uganda.
Peter OkuiNational Malaria Control Program, Ministry of Health, President's Malaria Initiative, Kampala, Uganda.
Charles KatureebeWorld Health Organization, President's Malaria Initiative, Kampala, Uganda.
Kassahun BelayUS Agency for International Development, President's Malaria Initiative, Kampala, Uganda.
Bryan K KapellaCenters for Disease Control and Prevention (CDC), President's Malaria Initiative, Kampala, Uganda.
Michelle A ChangMalaria Branch, Division of Parasitic Diseases and Malaria, CDC, Atlanta, Georgia.
Moses R KamyaDepartment of Medicine, Makerere University College of Health Sciences Infectious Diseases Research Collaboration, President's Malaria Initiative, Kampala, Uganda.
Sarah G StaedkeInfectious Diseases Research Collaboration, President's Malaria Initiative, Kampala, Uganda London School of Hygiene and Tropical Medicine, United Kingdom.
Grant DorseyDepartment of Medicine, University of California, San Francisco.
Philip J RosenthalDepartment of Medicine, University of California, San Francisco.
Infectious Diseases Research Collaboration · UGUniversity of California, San Francisco · USMinistry of Health · UGCenters for Disease Control and Prevention · UGDivision of Parasitic Diseases and Malaria · USMakerere University · UGWorld Health Organization - Uganda · UG

Funding

Transmission ProjectU19AI089674 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MATTHEW G DORSEY, MOSES Robert KAMYA · 2010 to 2026
$29.3M
Resistance of Malaria Parasites to Artemisinin-Based TherapiesR01AI075045 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSENTHAL, PHILIP JON · 2009 to 2024
$8.4M
NIAID NIH HHS R01 AI075045NIAID NIH HHS U19 AI089674World Health Organization 001
6 · The paper itself

Abstract

backgroundIn treating malaria in Uganda, artemether-lumefantrine (AL) has been associated with a lower risk of recurrent parasitemia, compared with artesunate-amodiaquine (AS/AQ), but changing treatment practices may have altered parasite susceptibility.

methodsWe enrolled 602 children aged 6-59 months with uncomplicated falciparum malaria from 3 health centers in 2013-2014 and randomly assigned them to receive treatment with AS/AQ or AL. Primary outcomes were risks of recurrent parasitemia within 28 days, with or without adjustment to distinguish recrudescence from new infection. Drug safety and tolerability and Plasmodium falciparum resistance-mediating polymorphisms were assessed.

resultsOf enrolled patients, 594 (98.7%) completed the 28-day study. Risks of recurrent parasitemia were lower with AS/AQ at all 3 sites (overall, 28.6% vs 44.6%; P < .001). Recrudescences were uncommon, and all occurred after AL treatment (0% vs 2.5%; P = .006). Recovery of the hemoglobin level was greater with AS/AQ (1.73 vs 1.39 g/dL; P = .04). Both regimens were well tolerated; serious adverse events were uncommon (1.7% in the AS/AQ group and 1.0% in the AL group). AS/AQ selected for mutant pfcrt/pfmdr1 polymorphisms and AL for wild-type pfcrt/pfmdr1 polymorphisms associated with altered drug susceptibility.

conclusionsAS/AQ treatment was followed by fewer recurrences than AL treatment, contrasting with older data. Each regimen selected for polymorphisms associated with decreased treatment response. Research should consider multiple or rotating regimens to maintain treatment efficacies.

Indexed as

AmodiaquineArtemether, Lumefantrine Drug CombinationArtemisininsChild, PreschoolDrug CombinationsEthanolaminesFemaleFluorenesHumansInfantMalaria, FalciparumMaleUgandaAmodiaquineamodiaquine, artesunate drug combinationArtemether, Lumefantrine Drug CombinationArtemisininsDrug CombinationsEthanolaminesFluorenesamodiaquine-artesunateartemether-lumefantrinedrug resistancemalariaUganda

Identifiers

PMID26597254
PMCPMC4836737
OpenAlexW2228511309

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.